In tuberculosis, successful anti-tubercular therapy leads to a marked reduction in ascites, resolution of septations, and regression of peritoneal thickening or nodularity within weeks to months with a fall in CA-125 levels. The gene discussed is MUC16; the disease is tuberculosis.